[go: up one dir, main page]

DE602006011959D1 - Na+, k+-atpase-expression bei zervixdysplasie und -krebs - Google Patents

Na+, k+-atpase-expression bei zervixdysplasie und -krebs

Info

Publication number
DE602006011959D1
DE602006011959D1 DE602006011959T DE602006011959T DE602006011959D1 DE 602006011959 D1 DE602006011959 D1 DE 602006011959D1 DE 602006011959 T DE602006011959 T DE 602006011959T DE 602006011959 T DE602006011959 T DE 602006011959T DE 602006011959 D1 DE602006011959 D1 DE 602006011959D1
Authority
DE
Germany
Prior art keywords
cervical
dysplasia
atpase
cancer
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006011959T
Other languages
English (en)
Inventor
Hiroaki Nitta
Thomas M Grogan
Phillip Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ventana Medical Systems Inc
Original Assignee
Ventana Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Medical Systems Inc filed Critical Ventana Medical Systems Inc
Publication of DE602006011959D1 publication Critical patent/DE602006011959D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G01N33/5755—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602006011959T 2005-12-30 2006-12-27 Na+, k+-atpase-expression bei zervixdysplasie und -krebs Active DE602006011959D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75522305P 2005-12-30 2005-12-30
US76444706P 2006-02-01 2006-02-01
PCT/US2006/049392 WO2007079128A1 (en) 2005-12-30 2006-12-27 Na+, k+-atpase expression in cervical dysplasia and cancer

Publications (1)

Publication Number Publication Date
DE602006011959D1 true DE602006011959D1 (de) 2010-03-11

Family

ID=38051860

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006011959T Active DE602006011959D1 (de) 2005-12-30 2006-12-27 Na+, k+-atpase-expression bei zervixdysplasie und -krebs

Country Status (10)

Country Link
US (1) US7851145B2 (de)
EP (1) EP1977246B1 (de)
JP (1) JP4960972B2 (de)
CN (1) CN101360998B (de)
AT (1) ATE456053T1 (de)
AU (1) AU2006332806B2 (de)
CA (1) CA2634896C (de)
DE (1) DE602006011959D1 (de)
ES (1) ES2340206T3 (de)
WO (1) WO2007079128A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2858359C (en) 2006-11-01 2018-04-03 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US20100068198A1 (en) * 2006-11-09 2010-03-18 Unibioscreen S.A. Targeting of alpha-1 or alpha-3 subunit of na+, k+-atpase in the treatment of proliferative diseases
US7985557B2 (en) 2007-05-23 2011-07-26 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
AU2008321225B2 (en) * 2007-11-13 2013-08-01 Phoenix Biotechnology Inc. Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside
US8703490B2 (en) 2008-06-05 2014-04-22 Ventana Medical Systems, Inc. Compositions comprising nanomaterials and method for using such compositions for histochemical processes
US20130107066A1 (en) * 2011-10-27 2013-05-02 Qualcomm Incorporated Sensor aided video stabilization
WO2017013648A1 (en) 2015-07-19 2017-01-26 Yeda Research And Development Co. Ltd. SELECTIVE INHIBITORS OF Alpha2-CONTAINING ISOFORMS OF Na,K-ATPase AND USE THEREOF FOR REDUCTION OF INTRAOCULAR PRESSURE
WO2017013637A1 (en) 2015-07-19 2017-01-26 Yeda Research And Development Co. Ltd. Selective inhibitors of alpha2-containing isoforms of na,k-atpase and use thereof for reduction of intraocular pressure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE302599T1 (de) 1996-05-24 2005-09-15 Angiotech Pharm Inc Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
CA2283636A1 (en) 1997-03-20 1998-09-24 Variagenics, Inc. Target genes for allele-specific drugs
WO1999024620A1 (en) 1997-11-10 1999-05-20 The Regents Of The University Of California Biochemical methods for detecting cervical dysplasia and cancer
AU2879300A (en) 1999-02-12 2000-08-29 Cellpath, Inc. Methods for anti-tumor therapy
GB0010683D0 (en) 2000-05-03 2000-06-28 Univ Bristol Cancer therapy
JP2003219880A (ja) * 2001-01-30 2003-08-05 Takeda Chem Ind Ltd 新規タンパク質およびそのｄｎａ
US6703400B2 (en) 2001-02-23 2004-03-09 Schering Corporation Methods for treating multidrug resistance
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20060148688A1 (en) * 2002-04-08 2006-07-06 Rajasekaran Ayyappan K Use of na, k-atpase a-and b-subunits in bladder cancer detection and drug screening
US6922586B2 (en) 2002-05-20 2005-07-26 Richard J. Davies Method and system for detecting electrophysiological changes in pre-cancerous and cancerous tissue
ATE519862T1 (de) * 2002-08-20 2011-08-15 Millennium Pharm Inc Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs
EP1608735A4 (de) * 2003-04-03 2008-11-05 Alnylam Pharmaceuticals Irna-konjugate
WO2005060951A2 (en) * 2003-12-19 2005-07-07 Bionaut Pharmaceuticals, Inc. Anti-neoplastic agents, combination therapies and related methods
US20050282893A1 (en) 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
KR20110027823A (ko) * 2004-03-24 2011-03-16 트리패스 이미징, 인코포레이티드 자궁경부 질환의 검사 방법 및 조성물
DK1781787T3 (en) 2004-08-23 2017-07-31 Sylentis Sau TREATMENT OF EYE DISORDERS FEATURED BY AN INCREASED INTRAOCULAR PRESSURE WITH SIRNAS
US20060135468A1 (en) 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using NA+/K+ ATPase inhibitors
US20060205679A1 (en) 2004-10-22 2006-09-14 Azaya Therapeutics, Inc. Topical and oral formulations of cardiac glycosides for treating skin diseases
TW200639252A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets
US7582441B1 (en) * 2005-10-17 2009-09-01 Celera Corporation Methods and compositions for treating and diagnosing disease

Also Published As

Publication number Publication date
AU2006332806A8 (en) 2011-10-20
JP2009522551A (ja) 2009-06-11
AU2006332806A1 (en) 2007-07-12
WO2007079128A1 (en) 2007-07-12
HK1124918A1 (zh) 2009-07-24
EP1977246A1 (de) 2008-10-08
CN101360998B (zh) 2015-12-02
JP4960972B2 (ja) 2012-06-27
CA2634896C (en) 2018-08-07
US20080286386A1 (en) 2008-11-20
EP1977246B1 (de) 2010-01-20
AU2006332806B2 (en) 2012-03-15
US7851145B2 (en) 2010-12-14
CA2634896A1 (en) 2007-07-12
ES2340206T3 (es) 2010-05-31
ATE456053T1 (de) 2010-02-15
CN101360998A (zh) 2009-02-04

Similar Documents

Publication Publication Date Title
AR061171A1 (es) Proteinas de union al factor de crecimiento de hepatocitos (fch)
EP2575884A4 (de) Anwendungen und zusammensetzungen zur behandlung von acne inversa
PH12012501067A1 (en) Combination therapy for treating cancer and diagnostic assays for use therein
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
MX374896B (es) Compuestos con actividad anticáncer.
DK1379510T3 (da) Aryl- og heteroarylurinstof Chk1-inhibitorer til anvendelse som radiosensibilisatorer og kemosensibilisatorer
PL1660507T5 (pl) Inhibitory proteazomu oraz sposoby ich stosowania
MX2010006203A (es) Derivados de pirazol y uso de los mismos como inhibidores de cinasas dependientes de ciclina.
ATE456571T1 (de) Proteasom-hemmer und verwendungsverfahren dafür
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
DOP2012000295A (es) Anticuerpos hacia gdf8 humano
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
EA200971053A1 (ru) Способы лечения кожных язв
MY160041A (en) Compositions and methods for treating parasitic infections
EA201290267A1 (ru) Производные диоксабицикло[3.2.1]октан-2,3,4-триола
MX389018B (es) Tratamiento de trastornos de adiccion y control de impulsos usando inhibidores de pde7.
EA201170160A1 (ru) Новые ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats)
TNSN07369A1 (en) Heteroaryl urea derivatives useful for inhibiting chki
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
CY1119317T1 (el) Συνθεση για τοπικη εφαρμογη, χρησεις αυτης, συσκευη εφαρμογης και kit μερων
WO2005112981A3 (en) Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
EA201100874A1 (ru) Соединения для лечения рака

Legal Events

Date Code Title Description
8364 No opposition during term of opposition